Interaction Checker

Cookies help us deliver our services. By using our services, you agree to our use of cookies. Learn more

Interactions with remdesivir updated to reflect QT risk

Tuesday 22 November 2022

CredibleMeds have reviewed the QT risk for the COVID-19 drug, remdesivir, and placed it in the Possible Risk category for torsade de pointes. Therefore, we have updated our interactions with the QT-prolonging HCC drugs lenvatinib and sorafenib from green to yellow.

We have also renamed the comedication Valproate (anticonvulsants class, known as Divalproex in the US) to help people find it. You will now find it listed as valproic acid, sodium valproate, and valproate semisodium.

Awards and commendations
bma-foundation-for-medical-research british-medical-journal-2018 queens_aniversary_prize_2017 rcp-excellence-patient-care-awards-2017 building_better_healthcare_awards_2016